Bluejay Diagnostics AI Stock Analysis
Want to see BJDX full AI Analyst Report?
Bluejay Diagnostics (BJDX) AI Stock Analysis
Bluejay Diagnostics
(NASDAQ:BJDX)
The overall score of 49 reflects a high-risk, pre-revenue medical device company. Financial performance is weak due to lack of revenue and ongoing losses, though corporate events provide optimism about clinical progress. Technical trends remain bearish, and valuation metrics are unfavorable. The stock is speculative with potential upside contingent on successful trial completion and regulatory approval.
Bluejay Diagnostics (BJDX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 326.58K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- -0.40
- Revenue Growth
- ―
- EPS Growth
- 95.46%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Bluejay Diagnostics Business Overview & Revenue Model
Company Description
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestra...
How the Company Makes Money
null
Bluejay Diagnostics Financial Statement Overview
Summary
Pre-revenue stage with significant net losses, though improving. Balance sheet shows low debt but declining equity. Cash flow negative, reliant on external funding. High-risk profile typical of pre-commercial biotech. Based on provided scores (Income Statement 15, Balance Sheet 30, Cash Flow 20) mapped to 37-99 range.
Income Statement
15Very NegativeBalance Sheet
30NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 249.04K | 0 |
| Gross Profit | -98.37K | 0 | 0 | 0 | 48.91K | 0 |
| EBITDA | -7.47M | -6.68M | -6.70M | -9.17M | -8.99M | -2.98M |
| Net Income | -7.68M | -6.85M | -7.72M | -9.95M | -9.30M | -3.73M |
Balance Sheet | ||||||
| Total Assets | 9.37M | 7.12M | 6.66M | 4.87M | 13.52M | 21.02M |
| Cash, Cash Equivalents and Short-Term Investments | 7.38M | 5.16M | 4.30M | 2.21M | 10.11M | 19.05M |
| Total Debt | 50.77K | 120.21K | 222.25K | 352.98K | 492.62K | 0 |
| Total Liabilities | 1.93M | 1.14M | 927.92K | 1.97M | 1.98M | 637.16K |
| Stockholders Equity | 7.44M | 5.98M | 5.73M | 2.89M | 11.54M | 20.38M |
Cash Flow | ||||||
| Free Cash Flow | -7.08M | -6.23M | -8.13M | -9.02M | -8.94M | -4.39M |
| Operating Cash Flow | -6.55M | -6.05M | -7.82M | -8.31M | -7.74M | -4.37M |
| Investing Cash Flow | -528.26K | -173.74K | -306.78K | -704.17K | -1.20M | -23.95K |
| Financing Cash Flow | 11.37M | 7.09M | 10.22M | 1.11M | 8,075 | 22.53M |
Bluejay Diagnostics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 2.15 is below the 20-day moving average (MA) of 2.38, below the 50-day MA of 3.01, and below the 200-day MA of 6.78, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 36.91 is Neutral, neither overbought nor oversold. The STOCH value of 28.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.
Bluejay Diagnostics Risk Analysis
Bluejay Diagnostics disclosed 59 risk factors in its most recent earnings report. Bluejay Diagnostics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBluejay Diagnostics Peers Comparison
Overall Rating
BJDX49Neutral
AEMD44Neutral
DHAI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $2.41M | -0.09 | -113.80% | ― | ― | 95.46% | |
| 44Neutral | $8.15M | -0.47 | -141.22% | ― | ― | 90.69% | |
| 40Underperform | $837 | 0.00 | 24.90% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BJDX | Bluejay Diagnostics, Inc. | 2.15 | -20.56 | -90.51% | |
| AEMD | Aethlon | 5.08 | -13.77 | -73.05% | |
| BBLG | Bone Biologics Corp | 0.31 | -1.26 | -80.32% | |
| DHAI | DIH Holdings US, Inc Class A | 0.02 | 0.00 | 0.00% |
Bluejay Diagnostics Corporate Events
Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
PositiveOn July 21, 2026, Bluejay Diagnostics announced it had completed patient enrollment in its SYMON-II multicenter clinical validation study ahead of schedule, reaching the target of 750 intensive-care sepsis patients. Conducted across leading U.S. inst...
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility
PositiveAt its June 9, 2026 annual meeting, Bluejay Diagnostics shareholders re-elected all incumbent directors and ratified Wolf & Company, P.C. as the independent auditor for the 2026 fiscal year, with quorum achieved from 414,092 of 1,034,715 eligible sha...
Bluejay Diagnostics Completes Private Placement to Extend Runway
PositiveOn June 2, 2026, Bluejay Diagnostics entered into securities purchase and registration rights agreements with institutional and accredited investors for a private placement of pre-funded warrants and Series G and H warrants tied to 3,655,917 shares o...
Bluejay Diagnostics Forms U.S. Manufacturing Partnership for Symphony
PositiveOn May 27, 2026, Bluejay Diagnostics entered an agreement with Argonaut Manufacturing Services for a suite of manufacturing services to support its Symphony platform and IL-6 testing products. The deal covers planning, engineering, supply chain manag...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Apr 08, 2026
